Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Iovance Biotherapeutics (IOVA) Net Margin (2023 - 2025)

Historic Net Margin for Iovance Biotherapeutics (IOVA) over the last 4 years, with Q3 2025 value amounting to 135.28%.

  • Iovance Biotherapeutics' Net Margin rose 73900.0% to 135.28% in Q3 2025 from the same period last year, while for Sep 2025 it was 158.79%, marking a year-over-year increase of 2923900.0%. This contributed to the annual value of 226.84% for FY2024, which is 371168100.0% up from last year.
  • Latest data reveals that Iovance Biotherapeutics reported Net Margin of 135.28% as of Q3 2025, which was up 73900.0% from 186.27% recorded in Q2 2025.
  • In the past 5 years, Iovance Biotherapeutics' Net Margin registered a high of 106.62% during Q4 2024, and its lowest value of 44750.0% during Q2 2023.
  • Its 3-year average for Net Margin is 11006.57%, with a median of 273.77% in 2025.
  • Its Net Margin has fluctuated over the past 5 years, first surged by 444379700bps in 2024, then skyrocketed by 73900bps in 2025.
  • Over the past 3 years, Iovance Biotherapeutics' Net Margin (Quarter) stood at 24140.66% in 2023, then surged by 100bps to 106.62% in 2024, then decreased by -27bps to 135.28% in 2025.
  • Its last three reported values are 135.28% in Q3 2025, 186.27% for Q2 2025, and 235.51% during Q1 2025.